Alkermes' sleep drug shows promise in early trial By Investing.com

Published on 9 Apr 2024 on Investing.com

Alkermes plc (NASDAQ:ALKS) announced promising results from a phase 1b study of its investigational...

Read the rest of the article

Start tracking your investments with Statfolio

Alkermes PLC (NASDAQ:ALKS) is set to release its Q3 2024 earnings on Oct 24, 2024. The consensus...

GuruFocus.com · via Yahoo Finance 23 Oct 2024

Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol ...

Zacks via Yahoo Finance 22 Apr 2024

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 16 Apr 2024

Alkermes plc ALKS announced positive top-line data from a phase Ib study evaluating its novel, in...

Zacks via Yahoo Finance 11 Apr 2024

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 10 Apr 2024

Alkermes (ALKS) stock gains on positive Phase 1b trial results for the company's oral sleeping...

Seeking Alpha 9 Apr 2024

Alkermes plc (NASDAQ:ALKS) announced promising results from a phase 1b study of its investigation...

Investing.com 9 Apr 2024

For new and old investors, taking full advantage of the stock market and investing with confidenc...

Zacks via Yahoo Finance 25 Mar 2024

Alkermes PLC (NASDAQ:ALKS), a global biopharmaceutical company, is focused on developing innovati...

GuruFocus.com via Yahoo Finance 18 Mar 2024

Alkermes plc (NASDAQ:ALKS) Q4 2023 Earnings Call Transcript February 15, 2024 Alkermes plc misses...

Insider Monkey via Yahoo Finance 16 Feb 2024